GSK-209762/147 (MeMuRu-147)

Study Sponsor: GSK

Study Title

Phase IV open study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK)Biologicals live attenuated Measles-Mumps-Rubella (MMR) vaccine when given to healthy children at the age of 12 to 18months in Singapore.

Medicine or Vaccine (generic name)

Measles, Mumps, Rubella Vaccine

Sponsor Identification Number

209762/147 (MeMuRu-147)

Trial Registry Identification Number(#'s)

NCT00388440

Medical Condition

Measles; Mumps; Rubella

Phase

Phase 4

Link to GSK Study Register

http://www.gsk-clinicalstudyregister.com/study/209762/147

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00388440

Link to study details on EudraCT (if available)

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report

Additional information about the data and documents available for this study

An annotated case report form is not available for this study. A blank case report form will be provided. A reporting and analysis plan is not available for this study.

Date Added to this Site

June 2015